KU
Kura Oncology, Inc.
KURA · NASDAQ
$11.20 -0.97% (-$0.11)
1M -8.35%
Market Cap $994.3M
P/E Ratio -
Div. Yield -
ROE 207.18%
Bulios Fair Price
$12.18
8.8% upside
Current Price
$11.2
Undervalued Fair Value Overvalued
According to Bulios Fair Price, KURA is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
0 /100
Expensive P/B 20.53x
P/S 12.88x
EV/EBITDA N/A
Growth
0 /100
Declining Book val. growth 25.45%
Rev. growth N/A
FCF growth N/A
Profitability
20 /100
Weak Net margin 384.30%
Op. margin 411.90%
FCF margin 152.06%
Quality
2 /100
Poor ROE 207.18%
ROA 50.49%
Asset turnover 0.13x
Debt
61 /100
Moderate Current ratio 4.73x
Int. coverage -208.21x
Debt/Equity 0.50x
Stability
43 /100
Moderate EPS volatility 33.38%
Profitable years 0
Beta 0.38x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about KURA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Troy Wilson
Employees
260
Headquarters
San Diego
Upcoming events
03 NOV
Earnings
Upcoming earnings report